Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. (Q48940179)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Vishakantha Murthy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Rizwan Basha Khatwal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Anil Dubala

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Santhivardhan Chinni

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Satish Kumar Muthureddy Nataraj

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Duraiswamy Basavan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

10 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacy and Pharmacology

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

1773-1784

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Common pathological processes in Alzheimer disease and type 2 diabetes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Vildagliptin: a new oral treatment for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Holeboard maze-learning deficits and brain monoaminergic neurotransmitter concentrations in rats after intracerebroventricular injection of 3-bromopyruvate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Comparison of neuroprotective effects of five major lipophilic diterpenoids from Danshen extract against experimentally induced transient cerebral ischemic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Current Treatment for Alzheimer Disease and Future Prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Cholinesterase inhibitors for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

2012 Alzheimer's disease facts and figures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

The role of amyloid beta peptide 42 in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Amyloid-β: the seeds of darkness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Alzheimer disease and diabetes mellitus: do they have anything in common?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Modeling sporadic Alzheimer's disease: the insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Developmentally regulated expression of specific tau sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

On the structure of microtubules, tau, and paired helical filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

(Val⁸) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJPHP.12148

21 January 2018

Identifiers

DOI

10.1111/JPHP.12148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24117480%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference